Literature DB >> 26058680

Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosis.

Edford Sinkala1,2, Melissa C Kapulu2,3, Ellen Besa2, Kanekwa Zyambo2, Ng'andu J Chisoso4, Graham R Foster5, Paul Kelly1,2,5.   

Abstract

BACKGROUND & AIMS: Cirrhosis is the main cause of portal hypertension worldwide but schistosomiasis dominates in much of the tropics. The seroprevalence of Schistosoma mansoni is up to 77% in endemic parts of Zambia. Morbidity is attributed to portal hypertension causing variceal bleeding which can be fatal. Bacterial translocation is associated with portal hypertension in cirrhosis but this is almost unexplored in hepatosplenic schistosomiasis. Liver biopsy is usually used to assess fibrosis although it is invasive and prone to sampling error. We aimed to investigate translocation, fibrosis and inflammatory makers in a case-control study of schistosomiasis at the University Teaching Hospital, Lusaka, Zambia.
METHODS: Patients had oesophageal varices, but were negative for human immunodeficiency virus, hepatitis B and C viruses. Plasma lipopolysaccharide binding protein was used as a marker of translocation while hyaluronan and laminin measured liver fibrosis. Inflammatory markers were measured in blood. Controls were patients with non-specific abdominal pain who had normal endoscopy.
RESULTS: Median (interquartile range) lipopolysaccharide binding protein was elevated in patients [44.3 ng/ml (35.7, 57.1)] compared to controls [30.7 ng/ml (30.4, 35.5), P < 0.0001]. Hyaluronan was higher in patients [111.6 ng/ml (39.1, 240.3)] compared to controls [21.0 ng/ml (12.4, 37.6), P < 0.0001] and so was laminin [2.2 μg/ml (1.0, 3.7)] compared to controls [0.9 μg/ml (0.7, 1.2), P = 0.0015]. Inflammatory markers, except C-reactive protein, were elevated in patients.
CONCLUSIONS: These data suggest that the bacterial translocation contributes to systemic inflammation in hepatosplenic schistosomiasis. Elevated fibrotic markers suggest they may be useful in diagnosing and monitoring periportal fibrosis.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bacterial translocation; fibrosis; inflammation; schistosomiasis

Mesh:

Substances:

Year:  2015        PMID: 26058680     DOI: 10.1111/liv.12891

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  13 in total

1.  Association between hepatitis B co-infection and elevated liver stiffness among HIV-infected adults in Lusaka, Zambia.

Authors:  Michael J Vinikoor; Lloyd Mulenga; Alice Siyunda; Kalo Musukuma; Roma Chilengi; Carolyn Bolton Moore; Benjamin H Chi; Mary-Ann Davies; Matthias Egger; Gilles Wandeler
Journal:  Trop Med Int Health       Date:  2016-08-30       Impact factor: 2.622

2.  Trends in upper gastrointestinal diagnosis over four decades in Lusaka, Zambia: a retrospective analysis of endoscopic findings.

Authors:  Violet Kayamba; Edford Sinkala; Stayner Mwanamakondo; Rose Soko; Boniface Kawimbe; Beatrice Amadi; Isaac Zulu; Jean-Baptiste Nzaisenga; Themba Banda; Chipasha Mumbwe; Evans Phiri; Philip Munkonge; Paul Kelly
Journal:  BMC Gastroenterol       Date:  2015-10-06       Impact factor: 3.067

3.  Direct Biomarkers of Microbial Translocation Correlate with Immune Activation in Adult Zambians with Environmental Enteropathy and Hepatosplenic Schistosomiasis.

Authors:  Patrick Kaonga; Evans Kaimoyo; Ellen Besa; Kanekwa Zyambo; Edford Sinkala; Paul Kelly
Journal:  Am J Trop Med Hyg       Date:  2017-11       Impact factor: 2.345

4.  Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial.

Authors:  Edford Sinkala; Kanekwa Zyambo; Ellen Besa; Patrick Kaonga; Bright Nsokolo; Violet Kayamba; Michael Vinikoor; Rabison Zulu; Martin Bwalya; Graham R Foster; Paul Kelly
Journal:  Am J Trop Med Hyg       Date:  2018-02-08       Impact factor: 2.345

5.  Derivation and external validation of a model to predict 2-year mortality risk of patients with advanced schistosomiasis after discharge.

Authors:  Guo Li; Shanshan Huang; Lifei Lian; Xiaoyan Song; Wenzhe Sun; Jinfeng Miao; Bohan Li; Yong Yuan; Shengfan Wu; Xiaoyan Liu; Zhou Zhu
Journal:  EBioMedicine       Date:  2019-08-23       Impact factor: 8.143

6.  Elevation of C-reactive protein, P-selectin and Resistin as potential inflammatory biomarkers of urogenital Schistosomiasis exposure in preschool children.

Authors:  Theresa N Chimponda; Caroline Mushayi; Derick N M Osakunor; Arthur Vengesai; Eyoh Enwono; Seth Amanfo; Janice Murray; Cremance Tshuma; Francisca Mutapi; Takafira Mduluza
Journal:  BMC Infect Dis       Date:  2019-12-19       Impact factor: 3.090

7.  Contribution of Schistosoma mansoni to systemic inflammation and microbial translocation among people with HIV in Zambia.

Authors:  Briana D Furch; Simutanyi Mwakamui; Sandie Sianongo; Kanekwa Zyambo; Douglas C Heimburger; John R Koethe; Paul Kelly
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-02-01       Impact factor: 2.455

8.  Hepatosplenic schistosomiasis in Zambian adults is characterized by increased liver stiffness: A nested case-control study.

Authors:  Edford Sinkala; Michael Vinikoor; Alice Miyanda Siyunda; Kanekwa Zyambo; Ellen Besa; Bright Nsokolo; Gilles Wandeler; Graham R Foster; Paul Kelly
Journal:  Heliyon       Date:  2020-07-28

9.  Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study.

Authors:  Edford Sinkala; Michael Vinikoor; Kanekwa Zyambo; Ellen Besa; Bright Nsokolo; Paul Kelly
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

10.  Nomograms to predict 2-year overall survival and advanced schistosomiasis-specific survival after discharge: a competing risk analysis.

Authors:  Guo Li; Lifei Lian; Shanshan Huang; Jinfeng Miao; Huan Cao; Chengchao Zuo; Xiaoyan Liu; Zhou Zhu
Journal:  J Transl Med       Date:  2020-05-06       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.